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Improved understanding of the cellular defects in heart failure enables the consideration of new therapeutic options to directly enhance Ca 2ϩ handling in failing myocytes. Parvalbumin (Parv) and SERCA2a are two key proteins involved in Ca 2ϩ handling in a variety of striated muscle types. SERCA2a is an ATP-dependent Ca 2ϩ pump that actively sequesters Ca 2ϩ into the sarcoplasmic reticulum (SR) during cardiac relaxation. Parv is a soluble Ca 2ϩ buffer that is naturally expressed in the cytoplasm of fast-twitch skeletal muscles but not in the heart. In fast-twitch skeletal muscles, Parv is thought to facilitate rapid muscle relaxation through the transient buffering of myoplasmic Ca 2ϩ . Recently, SERCA2a and Parv gene transfer have been shown to improve cardiac muscle myocyte relaxation via a more rapid decay rate in the calcium transient (5, 13, 30) . However, to date, there has been no direct comparison of the effects of Parv and SERCA2a on normal or diseased cardiac myocyte function under varied physiological conditions.
One aim of this study was to determine whether the overexpression of SERCA2a or the de novo expression of Parv would result in improved relaxation in individual myocytes from a large animal model of DD. Canine myocytes have Ca 2ϩ -handling properties that closely resemble those of human myocytes (3) . Accordingly, we established a model of pure DD in canines by ventricular pressure overload over a 1-yr time period that allowed for analysis of functional alterations with Parv and SERCA2a in a highly controlled heart failure system. Progressive left ventricular (LV) hypertrophy ensued, and, after 1 yr, DD with maintained systolic function was evident at both the whole organ and individual myocyte levels. In adult canine myocytes with DD, we report here the convergent, dose-dependent effects of Parv and SERCA2a to restore normal relaxation.
A second aim of the study was to assess SERCA2a-and Parv-transduced myocyte function under altered physiological conditions. Unexpectedly, we found that the characteristic marked increase in myocyte contractility by ␤-adrenergic stimulation was abrogated in SERCA2a-transduced myocytes, whereas it was retained in Parv-transduced myocytes. In concert with this finding, and in agreement with previous work, SERCA2a overexpression, but not Parv gene transfer, affects the stoichiometry between SERCA2a and phospholamban (PLB), a key inhibitor of SERCA2a activity. The differential outcomes of these Ca 2ϩ -handling proteins, particularly in terms of varied altered adrenergic reserve, may have implications for possible translation to human failing myocytes.
METHODS
Recombinant adenoviruses. The Parv and ␤-galactosidase (LacZ) recombinant adenovirus vectors were constructed as previously described (23) . The SERCA2a recombinant adenovirus vector contained the human cDNA for SERCA2a and a green fluorescent protein (GFP) reporter (the kind gift of Dr. Roger Hajjar, Harvard Medical School). In each vector, gene expression was under control of the cytomegalovirus promoter and polyadenylation signal provided by simian virus 40. High-titer, plaque-purified adenoviral stocks were produced and purified as described previously (23 In the DD group, DD was induced in five bred-for-purpose juvenile beagles (male, 5 kg). Nine age and size-matched control beagles served as comparisons [the noncoarctation (NC) group]. Progressive LV pressure overload was initiated by the placement of a descending thoracic aortic coarctation via a Gore-Tex interposition disc with a central 4-mm aperture via a left thoracotomy. Animals underwent serial transthoracic echocardiography every 2-4 wk for 1 yr. Systolic and diastolic blood pressure (obtained by pneumatic pressure cuff) for the DD dogs was 151.9 Ϯ 3.86 and 106.0 Ϯ 2.62 mmHg, respectively. Light sedation with 0.07 ml/kg BAG (100 mg butorphanol, 25 mg acepromazine, and 5 mg glycopyrolate/50 ml saline) was administered intramuscularly before evaluation. M-mode and two-dimensional echocardiography was performed transthoracically for the serial studies and epicardially during the final instrumentation. Short-axis LV views at the midpapillary level were used to measure septal and posterior wall thickness, transmitral E-to-A (E/A) ratio, and fractional shortening. The long-axis view was then obtained to complete LV mass determination. When maximal growth of the animal was achieved, the animals were instrumented via a median sternotomy with sonomicrometric piezoelectric crystals for hemodynamic monitoring during inflow occlusion (18) . Animals were induced with thiopental sodium, were maintained with isoflurane on a mechanical ventilator, and underwent a median sternotomy. Snares were placed around the superior and inferior vena cava. Hemispheric sonomicrometric piezoelectric crystals were placed on the long and short axis of the LV. A high-fidelity pressure transducer catheter (Millar Instruments; Houston, TX) was introduced through the LV apex for ventricular pressure monitoring. Fluid-filled arterial catheters were placed in the femoral artery and innominate artery for systemic pressure monitoring. Continuous pressure-volume loops were generated during repeated complete inflow occlusion. The end-diastolic pressure-volume relationship was determined for each animal. At the termination of the experiment, the animals were heparinized (500 U/kg) and euthanized with 1 ml/5 kg pentobarbital (390 mg/ml). The heart was explanted, immediately rinsed, and cooled in Krebs-Henseleit buffer (KHB) with calcium. Age-and weight-matched control animals (n ϭ 4) underwent identical hemodynamic monitoring before the heart was harvested.
Myocyte isolation and gene transfer. After 1 yr of pressure overload, the hearts were explanted, and KHB with supplemented calcium (118 mM NaCl, 4.8 mM KCl, 1.2 mM KH 2PO4, 1.2 mM MgSO 4 ⅐ 7H2O, 1.0 mM CaCl2 ⅐ 2H2O, 25 mM HEPES, and 11 mM glucose) was used to rinse the myocardium. The LV free wall was excised along with a cuff of the ascending aorta. The endocardium and epicardium were reapproximated to ligate the perforating vessels, and the left anterior descending coronary artery was cannulated. The ventricle was initially perfused on a modified Langendorf apparatus with KHB ϩ Ca 2ϩ until the heart started contracting and the effluent was clear. ). The average number of rod-shaped myocytes per heart was 6.87 ϫ 10 6 (Ϯ1.2 ϫ 10 6 ) with 51.4 Ϯ 2.6% viability in NC animals and 7.95 ϫ 10 6 (Ϯ1.4 ϫ 10 6 ) myocytes with 55.7 Ϯ 2.7% viability in DD animals. There were no significant differences in number or viability between NC and DD animals (t-test). Aliquots of myocytes (2 ϫ 10 4 myocytes) were plated on laminin-coated coverslips and incubated at 37°C in DMEM containing 5% fetal bovine serum, 50 U/ml penicillin, and 50 g/ml streptomycin for 2 h. After gentle aspiration, myocytes were incubated with recombinant adenovirus in serum-free DMEM plus penicillin/streptomycin (P/S). A total of four treatment groups were analyzed: control (media alone), LacZ [multiplicity of infection (MOI) 200], Parv (MOI 250), and SERCA2a (MOI 200). These optimal titers were derived from pilot studies demonstrating a high efficiency (at 48 h: LacZ staining 97%, GFP fluorescence 95%) without cytotoxicity. Serum-free medium was changed the day after viruses were added and then every 2 days for up to 4 days in culture.
Western blots and immunofluorescence. Myocytes were collected in sample buffer at days 0, 2, 3, and 4 postisolation. Samples were separated on SDS-polyacrylamide gels (3.5% acrylamide in the stacking gel, 12% acrylamide in the separating gel). The gel was then transblotted onto polyvinylidene difluoride membranes for 2,000 V ⅐ h. Immunodetection was carried out on blots fixed in glutaraldehyde. Western blot analysis was performed as described (31) with a Parv antibody (PARV19, Sigma) titer of 1:1,000, a SERCA2a antibody (SERCA2a, Upstate Biotechnology) titer of 1:1,000, a PLB (Upstate Biotechnology) titer of 1:1,000, or an anti-actin (5c5, Sigma) titer of 1:10,000. Individual blots were analyzed with Multi-analyst software (Bio-Rad) using actin immunolabeling to assess relative loading. Indirect immunofluorescence labeling of myocytes was performed as described (30) with primary [PARV19, 1:500; SERCA2a, 1:1,000; and PLB 1:500] and secondary (anti-mouse IgG-Texas red, 1:100, Molecular Probes) antibodies. Samples were examined on a Leitz Aristplan microscope outfitted with a Sony digital camera.
Laser diffraction and mechanical measurements. A diffraction chamber, as previously described (30) , was filled with M199ϩ (medum 199 stock, Sigma) supplemented with 10 mM glutathione, 26.2 mM sodium bicarbonate, 0.02% BSA, and 50 U/ml P/S (pH adjusted to 7.4 with NaOH), with 1.8 or 5 mM CaCl2. Temperature was set at 37°C. In each experimental group, an equal number of myocytes were evaluated at each calcium concentration. A supramaximal, 5-ms square-wave pulse was used to stimulate the myocytes. A myocyte was positioned in the laser beam, and the first-order diffraction line was focused with a cylindrical lens onto a linear position detector (LSC 5D or 30D, United Detector Technology). The output of the detector was amplified and recorded on a digital oscilloscope at 5,000 Hz. The average of 10 twitches/myocyte was used for subsequent analysis. After the above protocol, the detector was removed and a viewing screen was inserted in the beam path. The distance from the zero to the first-order diffraction pattern was used to calculate the initial sarcomere length (SL) and the amplitude of the SL change after electrical stimulation. The time from stimulation (T s) to maximum shortening/relengthening and from maximum shortening (Tp) to 1/4, 1/2, and 3/4 relengthening and the time to 1/2 width (T 1/4 R, T 1/2 R, and T 3/4 R, respectively) were measured from the averaged trace for each myocyte using Igor Pro wave-analysis software (Wavemetrics) The maximum rate of shortening and relengthening (ϩdL/dt max and ϪdL/dtmax, respectively) were calculated and normalized to the maximum shortening amplitude in each myocyte. ␤-Adrenergic stimulation was accomplished by adding 100 nM of isoproterenol to M199. All experiments involving isoproterenol were performed at 1.8 mM CaCl 2. Statistics. Statistical analysis was performed using GraphPad Instat software. For each dog, there were typically four experimental groups (control, LacZ, Parv, and SERCA2a), and data were assessed on days 2-4. On average, from each animal, 18 myocytes were studied ϫ3 time points ϫ4 experimental groups. This translates to a total of 216 myocytes for each dog on average. Thus, for the DD group, there were 5 dogs studied ϫ18 myocytes averaged/point ϭ an average of 90 myocytes/point. For the NC group, four dogs were studied. Observations per point vary somewhat between experiments due to some differences in the number of myocytes studied from day to day and from dog to dog. Results from dogs within the same group (NC or DD) were similar, as reflected by the errors reported in each group. Values for each group are expressed as means Ϯ SE. Significant differences between groups (P Ͻ 0.05) were tested with ANOVA and a post hoc Student-Newman-Keuls multiple-comparison test or by a Student's t-test if only two groups were compared.
RESULTS
Canine DD model. After 1 yr of LV pressure overload via descending thoracic aortic coarctation in canines, the animals maintained normal levels of activity without overt signs of heart failure (i.e., tachypnea, basal tachycardia, or exercise intolerance). Echocardiography indicated an increase in LV mass and preserved LV fractional shortening (Table 1) . Hypertrophy at the completion of the study was confirmed at the time of final instrumentation by increased LV mass (g/m 2 ) on epicardial echocardiography and increased LV posterior wall thickness (Table 1) . Systolic function was preserved, with the percent shortening fraction not different between control and DD animals ( Once developmental maturity and maximal growth had been attained, the control and DD animals underwent instrumentation with sonomicrometric piezoelectric crystals for hemodynamic monitoring during inflow occlusion challenges ( Table 2 ). The end-diastolic pressure-volume relation demonstrated an increase in the yintercept between control (1.0 Ϯ 4.17 mmHg) and DD (37.92 Ϯ 9.31 mmHg, P ϭ 0.008) animals and an increase in slope between NC (1.0 Ϯ 8.98 mmHg/ml) and DD (20.88 Ϯ 7.4 mmHg/ml, P ϭ 0.027) animals. These results provide evidence of decreased compliance and LV DD. Over the course of the study, all animals maintained normal levels of activity without evidence of overt heart failure.
To directly assess cellular function, adult myocytes were isolated from age-matched NC and DD animals. Impaired relaxation in DD versus NC myocytes was observed using laser diffraction analysis of SL shortening (Fig. 1A) . Values are means Ϯ SE; n, no. of animals. Pressure gradient is the mean arterial pressure in the forelimb minus the mean arterial pressure in the hindlimb measured with a pneumatic pressure cuff in the supine position. PW, posterior wall; SW, septal wall; LV, left ventricular; The P value was derived from a two-tailed t-test. remained stable over time (Western blot not shown) and the time-dependent increase in SERCA2a expression is demonstrated in Fig. 3A] .
Effects of Parv and SERCA2a on contractile performance. Contractile properties of DD myocytes were assessed initially at day 2 postgene transfer. Results from control (in all figures, "control" refers to nontransduced myocytes) NC myocytes and LacZ-transduced NC myocytes indicated that gene transfer per se had no significant effect on myocyte relaxation performance (Fig. 1C) . Similar results were exhibited with control and LacZ DD myocytes (results not shown). Thus all groups were subsequently compared with nontransduced control DD myocytes. At day 2 postgene transfer, alterations in relaxation were evident in SERCA2a-and Parv-expressing myocytes. Individual traces of Parv and SERCA2a myocyte shortening showed marked enhancement in the rate of relaxation, with restoration of relaxation to NC levels ( Fig. 2A) , with SERCA2a demonstrating significantly faster relaxation than control DD (P Ͻ 0.01) and Parv-expressing myocytes (P Ͻ 0.01). These findings are in keeping with earlier results demonstrating that SERCA2a and Parv hasten relaxation by facilitating a more rapid decay in the intracellular calcium transient (5, 13, 30) . Most evident at later time points in relaxation, SERCA2a was significantly more effective than Parv at accelerating relaxation (Fig. 2B) .
In general, the enhancement of the myocyte SL relengthening time course obtained by gene transfer of SERCA2a and Parv to DD myocytes was qualitatively similar in myocytes from NC animals ( Fig. 3 , A-C), and indirect immunofluorescence demonstrated that Ͼ90% of myocytes expressed Parv (Fig. 3D) . Western blot analysis showed that Parv increased from nondetectable levels at day 0 to Parv-to-actin ratios of 0.007 Ϯ 0.05 by day 2, 0.129 Ϯ 0.03 by day 3, and 0.169 Ϯ 0.01 by day 4. With the use of the rat fast-twitch extensor digitorium longus muscle as a positive control [Parv concentration ϳ0.33 mM (11)] and a transduced cardiac myocyte Parv-to-actin ratio of 3.62 Ϯ 0.7, the Parv concentration in myocytes at day 4 was estimated to be ϳ19 M. In SERCA2a-transduced myocytes there also was a time-dependent, progressive increase in ex- pression (Fig. 3A) . By day 4 postgene transfer, SERCA2a-transduced myocytes had a 40% increase in the SERCA2a-to-actin ratio compared with nontransduced controls. PLB expression remained stable from days 2 to 4. Therefore, the SERCA2a-to-PLB ratio increased over time, in agreement with previous studies (13) . Immunofluorescence imaging showed the expected striated pattern of SERCA2a expression in these myocytes, providing evidence that the overexpressed SERCA2a was localized to the SR (Fig. 3C) .
Because Parv and SERCA2a increased as a function of time postgene transfer, it is possible to construct a dose-response relationship for contractile function in DD myocytes by calculating the percent change from nontransduced DD myocytes at each corresponding day in primary culture. In this analysis, both Parv-and SERCA2a-transduced myocytes demonstrated a progressive decrease in T s 1/4 R from days 2 to 4, with values in transduced myocytes being significantly faster than the day-matched control DD myocytes (P Ͻ 0.01; Fig. 3A and Table 3 ). At days 2 and 3, SERCA2a-transduced myocytes had faster relaxation properties compared with those transduced with Parv (P Ͻ 0.01). However, owing to the progressive increase in Parv concentration by day 4, there was a marked acceleration in relaxation in Parv-transduced myocytes such that T s 1/4 R and T s 1/2 R were no longer different between the Parv and SERCA2a groups, although differences were still apparent in T s 3/4 R and ϮdL/dt between groups (Fig. 3, G and  H) . These results are consistent with Parv serving as a delayed buffer for calcium early in diastole and a source for calcium late in diastole. Figure 4 demonstrates that the absolute relaxation times were not different between NC and DD myocytes after Parv gene transfer. In contrast, with SERCA2a gene transfer, the relaxation times were significantly slower in DD compared with NC myocytes (Fig. 4B ). In association with increased Parv expression, there was a significant decrease in the relative sarcomere shortening that was not generally exhibited in SERCA2a myocytes (Fig. 3F) . As discussed recently, Parv, at high enough concentrations, can buffer systolic calcium and attenuate sarcomere shortening amplitude (5) .
Studies in NC canine cardiac myocytes demonstrated qualitatively similar alterations in relaxation and relative sarcomere shortening with similar dose-response curves (Table 3 
online).
In agreement with previous work in rodents (5, 26, 27) , the decay in the intracellular calcium transient was hastened by both Parv and SERCA2a (see Table 3 ). The decrease in shortening amplitude by increased Parv expression in isolated myocytes can be attributed to the heightened buffering of calcium, as discussed in detail previously (5) .
␤-Adrenergic stimulation. During ␤-adrenergic stimulation, both the amplitude of contraction (positive inotropy) and rate of relaxation are dramatically increased. We tested, under physiological Ca 2ϩ concentration (1.8 mM), whether Parv or SERCA2a gene transfer would affect the myocyte response to ␤-adrenergic stimulation (Fig. 5) . In nontransduced DD myocytes, ␤-adrenergic stimulation resulted in the characteristic enhancement of cellular contraction. In both Parv-and SERCA2a-transduced myocytes, ␤-adrenergic stimulation did not cause a further enhancement in relaxation (Fig. 5) . SERCA2a myocytes also were nonresponsive to ␤-adrenergic stimulation in terms of amplitude of contraction, whereas the Parv-transduced myocyte response, both qualitatively and quantitatively, was indistinguishable from control ( Fig. 5) . Thus, under ␤-adrenergic stimulation, the absolute magnitude of change in SL was no longer different between Parv and control and was markedly greater than that obtained with SERCA2a (Fig. 5B) . Qualitatively similar findings were obtained in NC myocytes transduced with Parv and SERCA2a vectors. To ascertain whether in SERCA2a-transduced myocytes this was caused by dysfunction in the ␤-adrenergic signaling cascade, or rather caused by a more generalized alteration in excitation-contraction coupling, myocytes were examined in the presence of heightened extracellular Ca 2ϩ (5 mM). Normally, heightened extracellular Ca 2ϩ produces enhanced Ca 2ϩ -induced Ca 2ϩ release in cardiac myocytes (Fig.  5D ). This mimics the positive inotropy seen with ␤-adrenergic stimulation but is independent of subcellular protein phosphorylation. In nontransduced DD myocytes, SL shortening increased to 211% of baseline by increasing Ca 2ϩ from 1.8 to 5 mM; however, in SERCA2a-and Parv-transduced myocytes the increase in SL amplitude was reduced (130% and 116%, respectively).
DISCUSSION
This study provides a direct comparison of SERCA2a and Parv on cardiac myocyte mechanical performance. A large animal model of pure hypertrophic DD with preserved systolic function was developed to provide a reproducible and controlled environment for assessing the functional consequence of genetic modification in Ca 2ϩ -handling proteins. In addition, myocytes from large mammals, as opposed to those from rodents, have intracellular Ca 2ϩ handling properties highly comparable with human cardiac muscle (3). Parv and SERCA2a gene transfer corrected relaxation abnormalities in failing myocytes in a similar dose-dependent manner. In contrast, whereas Parv-transduced and control myocytes responded to ␤-adrenergic stimulation with the typical marked increase in contractility (positive inotropy), SERCA2a-transduced myocytes were nonresponsive. As inotropy is a central effecter of overall cardiac performance, the divergent outcomes of these intracellular calcium handling proteins will likely be important in possible therapeutic translation to human heart failure.
Cardiac myocyte calcium handling is vital to overall heart function (3). In human heart failure, it is estimated that 40% of patients have pure DD (21) . Diastolic heart failure results in part by a decreased expression of SERCA2a; consequently, the intracellular calcium transient is prolonged and mechanical relaxation is slowed (27) . Considerable attention has been directed at the mechanisms of calcium handling in the normal and failing heart. Recent work has clearly demonstrated that modifications in either SERCA2a or PLB, an inhibitor of SERCA2a activity, markedly influence cardiac relaxation and may therefore have therapeutic potential in the failing heart. Decreased expression of PLB by gene ablation in mice or by antisense gene transfer has demonstrated the important role of the rate of calcium removal on heart and myocyte relaxation (7, 22) . Similarly, SERCA2a overexpression by transgenesis or by gene transfer can hasten relaxation kinetics (2, 13). Collectively, these studies provide strong evidence that the SR SERCA2a-to-PLB ratio is an important determinant of myocardial relaxation (19) .
The present findings, while supporting a role for SERCA2a in facilitating relaxation, provide evidence that an elevated SERCA2a-to-PLB ratio by SERCA2a gene transfer abrogates the contractile response of the myocyte to ␤-adrenergic stimulation. SERCA2a gene transfer results in increased SERCA2a content without alterations in PLB or other calcium-handling proteins, thus specifically increasing the SERCA2a-to-PLB ratio (27) . Our finding of disabled ␤-adrenergic-mediated inotropy in SERCA2a-transduced myocytes is comparable to that reported in myocytes from PLB knockout mice and in SERCA2a-overexpressing mice in vivo, which also have an increased SERCA2a-to-PLB ratio (20, 22) . The mechanism by which an increased SERCA2a-to-PLB ratio, achieved by SERCA2a overexpression or by PLB gene ablation, disrupts molecular inotropy is not known. One possibility is that increased SR calcium pump activity, caused by uncoupling of SERCA2a from its negative regulator PLB (4, 14) , alters the enhanced excitation-contraction coupling normally associated with ␤-adrenergic stimulation. Recent studies on myocytes from PLB knockout mice support this possibility. Calcium release events by SR calcium release channels [ryanodine receptors (RyR)] decayed more rapidly and produced increased occurrences of localized RyR calcium release failures in PLB knockout myocytes compared with the wild type (17) . That study concluded that enhanced local buffering by SERCA2a caused an increase in subcellular calcium gradients. SERCA2a overexpression, through a similarly heightened local buffering by the increased SR calcium uptake, may also affect signaling from diad to diad in the SR terminal cisternae, as apparent from myocytes from PLB knockout mice (17) . In this context, it is not immediately clear why the enhanced calcium buffering by Parv preserved molecular ␤-adrenergic-mediated inotropy, whereas SERCA2a did not (Fig. 5) . One possibility could relate to differences in their spatial localization within the myocyte. SERCA2a pumps are fixed spatially in the SR membrane in the relative vicinity of RyRs (3), whereas Parv is diffuse in the myoplasm (5). It is possible that the relative proximity of the overexpressed SERCA2a pumps to the RyRs could account for this observation. In addition, the newly expressed SERCA2a pumps are probably not all under regulation by PLB and, therefore, are already maximally functioning. With adrenergic stimulation, these pumps would not increase activity to further load the SR with Ca 2ϩ . In contrast, with Parv, the SERCA2a-to-PLB ratio is not altered so that enhanced SR loading and calcium release are retained with adrenergic stimulation. The preceding discussion of calcium buffering may also help explain why in SERCA-transduced myocytes heightened extracellular Ca 2ϩ (from 1.8 to 5 mM in the absence of adrenergic stimulation) did not augment contraction. It is not until extracellular Ca 2ϩ is raised to ϳ8 mM or higher or frequency of stimulation is increased that contractility is enhanced in SERCA2a-transduced myocytes (7) . It is unclear why Parv-transduced myocytes responded to adrenergic stimulation but not to elevated extracellular calcium in terms of positive inotropy (Fig. 5) . Further experimentation will be required to resolve these issues.
The present findings may have implications for human heart failure. Diastolic heart failure in particular is increasing in incidence and is the leading cause of hospitalization in the elderly. There are no direct clinical treatments for diastolic heart failure. Efforts to improve calcium handling in diseased myocardium hold promise toward the remediation of slow relaxation in human heart failure (6, 9, 12, 16, 29) . In this light, the divergent effects of Parv and SERCA2a in canine myocytes in the presence of inotropes may have direct applicability to failing human myocytes. In particular, the distinguishing properties of Parv and SERCA2a gene transfer shown here are likely important given the clinical relevance of inotropic reserve and interventions and therapies for the normal and failing heart. Under the present experimental conditions, SERCA2a was found to affect molecular inotropy. In comparison, at high concentrations, Parv altered contraction in the absence but not presence of inotropes. Future organ level studies in higher mammalian species, and under various pathophysiological conditions, will be important to complement these results from canine isolated myocytes and hearts from transgenic mice. Collectively, the results of this study provide a foundation to further the advancement of experimental therapeutics focused on restoring normal Ca 2ϩ characteristics for patients with heart failure.
